2CB7
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2CB7, also known as 2C-B-5-hemiFLY-β7, is a serotonin receptor modulator of the phenethylamine, 2C, and benzofuran families related to 2C-B.[1][2][3][4] It is a cyclized phenethylamine or conformationally restrained derivative of 2C-B in which the 5-methoxy group has been cyclized into a dihydrofuran ring and the β position has been connected with the dihydrofuran ring via a propyl group to form a cycloheptane ring to form a tricyclic structure.[1][2][3][4]
- None
 | |
| Clinical data | |
|---|---|
| Other names | 2C-B-5-hemiFLY-β7 |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C14H18BrNO2 |
| Molar mass | 312.207 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The compound has syn and anti stereoisomers, with these isomers also being racemic mixtures of (+)- and (–)- enantiomers.[1][2][3][4] The isomers of 2CB7 show affinity for the serotonin 5-HT2A receptor, with values (Ki) of 74 to 170 nM for syn-2CB7 and 170 to 200 nM for anti-2CB7.[1][2][3][4] These affinities were dramatically lower than those of 2C-B (Ki = 0.66–0.88 nM).[1][2][3][4]
2CB7 was first described in the scientific literature by Michael Robert Braden and David E. Nichols and colleagues in 2006.[1][2][3][4] It was developed as part of scientific research into serotonin 5-HT2A receptor ligand interactions.[3][4]